CETP and type 2 diabetes mellitus: A similar result was obtained in the Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition with Evacetrapib in Patients with at High Risk for Vascular Outcomes (ACCELERATE) trial, where glycaemic control was found to be improved in T2D patients [63].